NBE Therapeutics today announces that the company has raised additional seed-financing from the Boehringer Ingelheim Venture Fund (BIVF). The amount of financing is not disclosed. The proceeds will be used to fully establish NBE-Therapeutics proprietary Transpo-mAb® antibody discovery and enzymatic antibody-payload conjugation technologies, and to develop the first "next-generation" ADC product candidates.